Physician profile
Gregory V Maynard
NPI 1063450187
$10,915.33
in general payments reported to CMS, 2019-2025
42 companies · $1,496 in 2025
The $1,496 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,062 · 2020: $1,459 · 2021: $1,687 · 2022: $1,294 · 2023: $1,398 · 2024: $1,521 · 2025: $1,496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,394 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,393.79 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,038.22 | 2019-2025 | Farxiga, Breztri |
| Abbvie INC. | $1,028.88 | 2021-2025 | |
| Amgen INC. | $997.42 | 2019-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $915.61 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $895.47 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Novo Nordisk INC | $826.98 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $660.62 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $482.02 | 2019-2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $431.11 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $401.50 | 2019-2023 | Belsomra, Verquvo, Steglatro |
| Bayer Healthcare Pharmaceuticals INC. | $400.95 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $400.75 | 2019-2025 | Jardiance |
| Allergan, INC. | $262.06 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $196.32 | 2022-2025 | Rexulti |
| Lundbeck LLC | $183.59 | 2022-2025 | Rexulti, Vyepti |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Maynard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.